Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al
It is not the first time the TGA has issued such a warning, with the viral weight-loss drugs popularity showing no signs of slowing down
Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications
It is a good fit for you if: You are 18 to 75 You have a body mass index (BMI) of 30 to 39 or 27-29 with qualifying weight-related health conditions You do not have coverage for weight loss medications You do not have health conditions that restrict your ability to safely take weight loss medications and participate in the program MWMRx is only available to those who do not currently have coverage for weight loss medications since it is a fee for service program
It is for educational purposes only and should not be used for the diagnosis, treatment, or prevention of diseases
The crude reaction mixtures in 96-well format were directly screened for cathepsin B inhibitory activity in a fluorometric endpoint assay 57
